Clinical Trial Update: A-RGEMOX in the Treatment of Early Relapsed/Refractory DLBCL [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating A-RGEMOX for early relapsed/refractory diffuse large B-cell lymphoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Gemcitabine (Gemcitabine)
• OXALIPLATIN (Oxaliplatin)
• Rituximab (rituximab)

Snippet

Sponsor: Zhejiang Cancer Hospital | Conditions: Diffuse Large B-cell Lymphoma Recurrent, Diffuse Large B Cell Lymphoma Refractory | Phase 2 | Status: RECRUITING